arrow
A

Adam L. Asare

University of California San Francisco
H指数:27
被引数:5,215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

系统化数据捕获减少了源数据验证的需求:一项来自一项多中心随机对照平台试验的探索性分析

2025-10-290
OAAI
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-141
PRE
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

2024-09-144
PRE
The Association Between Symptom Severity and Physical Function among Participants in I-SPY2
2023-03-010
PRE
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
2022-12-0112
OA
Treatment Efficacy Scored-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
2022-08-0112
OAAI
Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study
2022-02-151
PRE
Clinical trial design during and beyond the pandemic: the I-SPY COVID trial
2022-01-2013
OA
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

新辅助T-DM1/帕妥珠单抗和紫杉醇/曲妥珠单抗/帕妥珠单抗治疗HER2乳腺癌的适应性随机I-SPY2试验

2021-11-0542
OAAI
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
2021-10-0524
OA
Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
2015-06-26122
OAAI
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
2013-08-01584
OA